Can cyclin D1 be utilized as a second step &amp;#147;after basal cell marker&amp;#148; for both diagnosis and prognosis of prostatic adenocarcinoma?

Atta, Ihab Shafek; Eid, Aly Gomaa; El-Hag, Mohamed Atta; AlQahtani, Faisal Fahd

doi:10.5455/ijmsph.2016.28122015311

Int J Med Sci Public Health

2016

DOI: 10.5455/ijmsph.2016.28122015311

|View full text |Cite

Can cyclin D1 be utilized as a second step after basal cell marker for both diagnosis and prognosis of prostatic adenocarcinoma?

Ihab Shafek Atta¹,

Aly Gomaa Eid²,

Mohamed Atta El-Hag³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there are data suggesting the relation between overexpression of DJ-1, cyclin D1 and androgen receptor (AR) status. [6,7] The aim of this study is to evaluate the expression level of cyclin D1 and DJ-1 in BPH and PC, correlation with clinicopathological features and assess the sensitivity and specificity of both as immune-markers in discerning some embarrassing cases.…”

mentioning

confidence: 99%

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Mohammed

Ibrahim

Atwa

et al. 2019

Forum of Clinical Oncology

View full text Add to dashboard Cite

BackgroundDisturbance in cell cycle regulatory genes is a common finding among many types of cancers. The aim of this study is to evaluate the role of cyclin D1 and DJ-1 in benign prostatic hyperplasia (BPH) and prostate cancer (PC).MethodThe current study enclosed 40 patients diagnosed with PC and 40 cases of BPH. The expression level of cyclin D1 and DJ-1 were evaluated by immunohistochemistry (IHC). Cyclin D1 scored depending on the percentage of stained nuclear tumor cells. While scoring of DJ-1 was based on intensity. The results were correlated with clinicopathological features and outcome.ResultsIn the PC group, cyclin D1 was detected in 95% and overexpressed in 42.5%, DJ-1 was positively stained in 85% and overexpressed in 47.5%. Meanwhile, in the BPH group, cyclin D1 was not detected and DJ-1 stained in only 2.5%. There was a statistically significant difference in Gleason score (GS), tumor stage, size, and treatment failure (p =< 0.001). In the terms of PC diagnosis prediction, although cyclin D1 was more specific (100%), DJ-1 is more sensitive than cyclin D1 (80%, 70%, respectively) (p = 0.000).ConclusionsCyclin D1 and DJ-1 may emerge as a promising way for diagnosis of PC in certain circumstances, as the presence of insufficient tissue sampling, small foci of carcinoma or benign lesions mimic PC. This is in addition to the known role of cyclin D1 and DJ-1 in PC prognosis.

show abstract

mentioning

confidence: 99%

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Mohammed

Ibrahim

Atwa

et al. 2019

Forum of Clinical Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Can cyclin D1 be utilized as a second step after basal cell marker for both diagnosis and prognosis of prostatic adenocarcinoma?

Cited by 1 publication

References 0 publications

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Contact Info

Product

Resources

About